Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Rating of “Buy” by Brokerages

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has received an average recommendation of “Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and four have given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $11.8889.

CATX has been the subject of several research analyst reports. Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Monday, October 20th. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Saturday, July 12th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research note on Friday, October 3rd. Finally, BTIG Research initiated coverage on shares of Perspective Therapeutics in a research note on Friday, October 10th. They issued a “buy” rating and a $14.00 price objective for the company.

Institutional Investors Weigh In On Perspective Therapeutics

Several hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in shares of Perspective Therapeutics during the third quarter worth about $46,000. BNP Paribas Financial Markets boosted its stake in shares of Perspective Therapeutics by 227.1% during the second quarter. BNP Paribas Financial Markets now owns 242,610 shares of the company’s stock worth $835,000 after buying an additional 168,448 shares during the period. Bank of America Corp DE boosted its stake in shares of Perspective Therapeutics by 8.5% during the second quarter. Bank of America Corp DE now owns 327,500 shares of the company’s stock worth $1,127,000 after buying an additional 25,697 shares during the period. Federated Hermes Inc. boosted its stake in shares of Perspective Therapeutics by 44.4% during the second quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock worth $671,000 after buying an additional 60,019 shares during the period. Finally, Walleye Capital LLC boosted its stake in shares of Perspective Therapeutics by 375.8% during the second quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock worth $645,000 after buying an additional 148,013 shares during the period. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Trading Up 3.8%

NYSEAMERICAN:CATX opened at $2.99 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 15.09 and a quick ratio of 15.09. Perspective Therapeutics has a 12 month low of $1.60 and a 12 month high of $12.90. The business’s fifty day moving average price is $3.56 and its 200 day moving average price is $3.27.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.